Back to Search
Start Over
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma
- Source :
- Anticancer Research. 39:4925-4931
- Publication Year :
- 2019
- Publisher :
- Anticancer Research USA Inc., 2019.
-
Abstract
- BACKGROUND/AIM Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy where antioxidant enzyme peroxiredoxin 6 (Prx6) has previously been associated with adverse outcomes. Its systemic effects in DLBCL are unknown. MATERIALS AND METHODS This study included 53 patients with DLBCL, five patients with primary central nervous system lymphoma (PCNSL) and 20 healthy controls. The expression of Prx6 was evaluated immunohistochemically in DLBCL tissue samples and compared to its expression in blood serum. RESULTS Prx6 expression was the highest in healthy controls, followed by DLBCL patients and PCNSL patients. Febrile neutropenic infection after the first treatment course was associated with low pre-treatment Prx6 serum levels (
- Subjects :
- Adult
Male
Cancer Research
medicine.medical_specialty
Neutropenia
Infections
Malignancy
Risk Assessment
Gastroenterology
Blood serum
Risk Factors
immune system diseases
hemic and lymphatic diseases
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Humans
Medicine
Adverse effect
Aged
Neoplasm Staging
Aged, 80 and over
business.industry
Primary central nervous system lymphoma
Cancer
General Medicine
Middle Aged
medicine.disease
Lymphoma
Oncology
Female
Lymphoma, Large B-Cell, Diffuse
business
Diffuse large B-cell lymphoma
Biomarkers
Peroxiredoxin VI
Subjects
Details
- ISSN :
- 17917530 and 02507005
- Volume :
- 39
- Database :
- OpenAIRE
- Journal :
- Anticancer Research
- Accession number :
- edsair.doi.dedup.....5df0b31d50a29662eaa4781a7971b479